Clinical trial NCT01307540: Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients
Official title: Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Mucosal Ulceration
Oral Mucositis
Oral Lesion
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2011-03-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Primary purpose: PREVENTION

Brief summary: Study hypothesis: light therapy may prevent oral ulcers in bone marrow recipients.

Methods: patients will be treated with either active light-emitting device or inactive light-emitting device. Daily treatment with light therapy will start at the beginning of the conditioning regimen and will last until day 21 post-transplant. Each daily treatment last about 5 minutes. Patients will be evaluated for oral mucositis and oral pain level on a weekly basis.

Detailed description: Primary endpoint:

o Assessment of effectiveness of treatment with QRay1 in preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT).

Secondary endpoint:

* Assessment of mucositis associated- pain relief.
* Assessment of safety of treatment with QRay1 (oral adverse events).
* Assessment of the patients' acceptance of the device.

Study design:

Double-blind, randomized, placebo-controlled, 2 groups (randomization ratio 1:1).

Duration of treatment:

Daily treatment. Study-treatment administration began at the initiation of conditioning regimen (visit 1) and continued to day 28 or at least until day 21 if the patient had no mucositis (WHO or OMAS = "0")

Light radiation dose:

60-70mW/cm2 (administered over 3 treatment areas), starting with 45 seconds per surface, increasing each day in intervals of 15 seconds, up to a maximum of 90 seconds per surface.

Evaluation plan:

Evaluation began before the conditioning regimen was initiated (visit 1) and continued weekly until day 28 or until day 21 if the patient had no mucositis. A follow-up evaluation was performed a month after discharge the patient. Unusual clinical presentation was addressed whenever observed.

Criteria for evaluation:

Primary efficacy variable:

o Rate of absent of mucositis at any of the visits using WHO scale for mucositis and OMAS.

Secondary efficacy variables:

* Severity of oral mucositis at any of the visits using WHO scale for mucositis and OMAS.
* Severity of oral pain at any of the visits using WHO scale for mucositis and OMAS.
* Safety (oral adverse events)
* Patients' acceptance of the study drug on an 11-step ladder. Others
* Compliance with standard oral care (chlorhexidine rinse, nystatin readymix, saline mouthwash)

Eligibility criteria: Inclusion Criteria:

* No oral ulceration at baseline
* At risk for oral mucositis due to the conditioning regimen to HSCT
* Age above 18 years old
* Karnofsky score \>60
* Agree to participate in the study (signed an informed consent)

Exclusion Criteria:

* Pregnant woman
* Well-founded doubt about the patient's jurisprudence
* Children
* Sensitivity to light or treated with drugs which are sensitizers to light
* Treatment with other experimental topical drug during the study period

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: